オプションチェーンは、Pasithea Therapeuticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Pasithea Therapeuticsの市場センチメントを評価します。.

Pasithea Therapeutics (NASDAQ:KTTA) 株価情報, オプションチェーン

Pasithea Therapeutics

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics Corp

WIIM

RIGL

RIGL stock has given up its prior gain. Rigel Pharmaceuticals shares were trading higher after the company reported Q1 financial results and beat its EPS and sales estimates.

Movers

Trading Ideas

NTCL

NETCLASS TECHNOLOGY Shares Halted For Volatility

At their meeting held today, the Board of Directors of Chesapeake Utilities Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPK#NYSE">CPK</a>) voted to increase the quarterly cash dividend on the Company's common stock from $0.64 per share to $0.685 per share. The Board's action raises the 2025 annualized dividend by $0.18 from $2.56 to $2.74 per share, a 7 percent increase. The $0.685 per share dividend will be payable July 7, 2025 to all shareholders of record at the close of business on June 16, 2025.

News

Dividends

Chesapeake Utilities Increases Quarterly Cash Dividend From $0.64 To $0.685/Shr; Ups Annualized Dividend By 7% From $2.56 To $2.74/Shr

IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) held its Think 2025 event in <a href="https://www.benzinga.com/25/05/45259042/ibm-thinks-big-ai-delivers-bigger-why-bulls-are-charging-toward-300">Boston on Tuesday. </a> 
The key takeaway from the event is the company's portfolio of software products and services being "integral to large enterprise customers as they leverage AI across their organizations," according to Goldman Sachs.
The IBM Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5805f8a2846faa000106ab15/james-schneider">Analyst James Schneider</a> maintained a Buy rating and price target of $270.
The IBM Thesis: The company launched LinuxONE 5, which enables 450 billion secure AI inference operations per day, Schneider said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
The company also introduced an upgraded watsonx.data, which taps unstructured data to increase accuracy of AI agents, he added.
"CEO Arvind Krishna noted that AI is shifting from experimentation to delivering measurable business value, with an emphasis on productivity and cost efficiency," the analyst wrote.
IBM projected that AI agents could power 30% of the one billion new applications by 2028, he further stated.
By applying its AI solutions internally, the company can "support ongoing margin expansion and FCF growth &#8211; even as it executes on M&amp;A," Schneider said.
IBM Price Action: Shares of IBM were up 1.1% to $252.02 at the time of publication on Wednesday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45218573/ibms-ai-watsonx-integrates-with-oracle-cloud-to-boost-enterprise-productivity">IBM AI Watsonx Integrates With Oracle Cloud To Boost Enterprise Productivity</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Reiteration

Analyst Ratings

IBM's AI Push Takes Center Stage At Think 2025, Goldman Sees Path To Margin Growth

XChange TEC.INC shares are trading lower after the company announced plans to change its ADS ratio from 1-to-120 to 1-to-2400.

Hedge Funds

General

Doubleline Capital's Gundlach Says We're In A Risk-off Market On Intermediate Term Basis

GLBZ

Glen Burnie shares are trading lower after the company reported a year-over-year decrease in Q1 sales results.

Chardan Research initiated coverage on Praxis Precision Medicines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) on Wednesday, citing the potential of its <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">epilepsy franchise</a>.
Analyst Rudy Li writes, &#8220;Epilepsy remains one of our favorite markets in the CNS space, and we view Praxis as a diversified play in epilepsy, with a portfolio of products leveraging validated drug targets.&#8221;
Praxis had $472.0 million in cash, cash equivalents, and marketable securities as of March 31, which is expected to fund operations into 2028.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40691948/praxis-precision-medicines-touts-encouraging-data-for-mid-stage-epilepsy-drug" rel="noreferrer noopener">Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug</a>
In March, Praxis released interim data from Study 1 of the Essential3 program of ulixacaltamide&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44087912/analyst-cut-price-targets-for-praxis-precision-after-trial-setback-for-essential-tremor-candidate" rel="noreferrer noopener">in essential tremor (ET)</a>.
The Independent Data Monitoring Committee recommended stopping the study for futility. The results are unlikely to meet the primary efficacy endpoint.
<ul>
<li>&#8220;While we believe that the Phase 3 studies are unlikely to work (and we have not modeled for), we believe it is also possible that the FDA could provide regulatory flexibility given the unmet need for ET, which could provide additional upside to the story,&#8221; analyst Li writes.</li>
<li>In its first-quarter earnings release, the company said it decided to complete the studies and will share topline results in the third quarter of 2025. After reviewing the results of both studies, Praxis will decide if there is sufficient evidence to <a href="https://www.benzinga.com/pressreleases/25/05/g45164110/praxis-precision-medicines-provides-corporate-update-and-reports-first-quarter-2025-financial-resu" target="_blank" rel="noreferrer noopener">support an NDA filing</a>.</li>
</ul>
The analyst initiated with a Buy rating and a<a target="_blank" href="https://www.benzinga.com/quote/PRAX/analyst-ratings" rel="noreferrer noopener"> price forecast of $80</a>.
Chardan is optimistic <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37941441/why-praxis-precision-medicines-stock-is-trading-higher-tuesday" rel="noreferrer noopener">about vormatrigine&#8217;s (formerly PRAX-628) potential</a> in treating major types of epilepsy, especially focal onset seizures and generalized epilepsy, with possible peak sales over $1 billion.
<ul>
<li>As a next-generation sodium channel modulator, vormatrigine stands out from older drugs and current standard treatments because of its strong potency and targeted action, which could lead to better effectiveness and fewer side effects.</li>
<li>Early trials showed it has a wide safety margin, and a separate study showed high response rates in patients with light-triggered seizures.</li>
</ul>
Talking about Praxis&#8217;s elsunersen, an antisense product, Chardan writes that the product could become the first disease-modifying therapy for the treatment of SCN2A Gain-of-Function (GoF) DEE, which is a rare indication (~2K patients)
Price Action: PRAX stock is up 7.31% at $37.74 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45257204/chinese-biotech-beigene-stock-falls-despite-strong-brukinsa-sales-and-earnings-beat" target="_blank" rel="noreferrer noopener">Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Initiation

PRAX

Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside

DRCT

Direct Digital Holdings shares are trading lower after the company reported worse-than-expected Q1 financial results. Also, Benchmark lowered its price target on the stock from $8 to $6.

ASST

Asset Entities Shares Halted On Circuit Breaker To The Upside, Stock Now Up 345.9%

Applovin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares are facing selling pressure again after short seller Muddy Waters Research released a bearish report on the company, which follows an initial <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44524167/applovin-shares-fall-20-following-muddy-waters-report-on-alleged-platform-violations-whats-going-on">short report from March</a>. 
What To Know: AppLovin shares sold off in March after Muddy Waters announced a short position, calling AppLovin &#8220;another scammy adtech company&#8221; that relies on retargeting for e-commerce conversions.
AppLovin executives responded to the short report in a <a href="https://www.applovin.com/blog/note-from-our-ceo-2/">blog post</a> that Muddy Waters says includes &#8220;demonstrably false&#8221; statements. The company also hired a law firm to perform &#8220;an independent review and investigation into recent short report activity targeting the Company.&#8221;
Muddy Waters on Wednesday alleged that AppLovin continues to use persistent identifiers that violate user privacy and partner&#8217;s terms of service, which AppLovin executives denied in a subsequent <a href="https://www.applovin.com/blog/how-we-drive-value-and-handle-data/">blog post</a>, the short seller said. 
Benzinga has reached out to AppLovin for comment on the report. 
&#8220;On March 31, Foroughi denied that APP creates or uses persistent identity graphs (PIGs) for users who decline IDFA cross &#8211; application tracking. On May 1, APP re-upped Foroughi's lie by recycling his March 31 post in a newsletter to stakeholders,&#8221; Muddy Waters said. 
&#8220;This presentation and the accompanying video show records of web and application traffic that prove these claims to be utterly false. We show that persistent identifiers are created, disguised, and applied to track users across domains and applications.&#8221;
The full short report can be found <a href="https://muddywatersresearch.com/wp-content/uploads/2025/05/MW_APP_20250507.pdf">here</a>. Benzinga&#8217;s previous coverage is also available via <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44524167/applovin-shares-fall-20-following-muddy-waters-report-on-alleged-platform-violations-whats-going-on">this link</a>. 
AppLovin is due to report first-quarter financial results after the market close on Wednesday. Analysts expect the company to report earnings of $1.45 per share and revenue of $1.38 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. Investors will be watching for a potential response from the company in the earnings call, scheduled for 5 p.m. ET.
APP Price Action: AppLovin shares were down 2.4% at $297.30 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
AppLovin shares are down about 8% year-to-date, but the stock is still up more than 300% over a one-year period.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/05/45126778/short-seller-jim-chanos-slams-trumps-reindustrialization-hopes-says-3-per-hour-apple-supplier-foxconn-workers-were-too-expensive-questions-if-those-jobs">Short Seller Jim Chanos Slams Trump&#8217;s Reindustrialization Hopes: Says $3-Per-Hour Apple Supplier Foxconn Workers Were &#8216;Too Expensive&#8217; — Questions If &#8216;Those Jobs Are Coming Back&#8217;</a></li>
</ul>
Photo: Shutterstock.

Short Sellers

Muddy Waters Doubles Down On AppLovin In New Short Report Ahead Of Q1 Earnings

Shares of DoorDash Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) tanked in early trading on Wednesday after the company announced downbeat first-quarter sales on Tuesday.
Here are some key analyst takeaways.
Wedbush On DoorDash
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58459503ee7bf6000154d075/scott-devitt">Analyst Scott Devitt</a> maintained a Neutral rating while raising the price target from $190 to $200.
DoorDash's revenue grew 20.7% year-on-year to $3.0 billion but came in below Street expectations of 22.8% growth, Devitt said in a note. He added, however, that the company's Gross Order Value (GOV) grew by $23.1 billion, ahead of consensus estimates of $22.9 billion.
Management guided to GOV growth in the range of 18.2%-20.2% for the second quarter, beating consensus by around 90 basis points at the midpoint "as the company continues to execute on its growth initiatives across international markets and new verticals," the analyst stated. "Despite ongoing macro uncertainty in the US, we are encouraged by the growth trajectory for the full year implied by the strength of the 2Q GOV guide," he further wrote.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Needham On DoorDash
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587635595064ed000140010c/scott-berg">Analyst Bernie McTernan</a> reaffirmed a Buy rating, while lifting the price target from $225 to $230.
McTernan said DoorDash announced the acquisitions of UK-based Deliveroo and hospitality software operator SevenRooms. While Deliveroo helps the company expand its total addressable market, SevenRooms complements the capabilities of its commerce platform.
DoorDash generated 19.9% year-on-year GOV growth in the first quarter and guided to 19.2% growth in the second quarter, the analyst stated. The company's better bookings performance is being driven by investments in affordability, which could pressure margins in the near-term margin but "should pay off over the long-term given the higher order frequency and retention of DashPass subscribers," he wrote.
Cantor Fitzgerald On DoorDash
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/596f57cb35f48b00011db3ec/deepak-mathivanan">Analyst Deepak Mathivanan</a> reiterated an Overweight rating and price target of $210.
DoorDash first-quarter performance and second-quarter guidance reflect that "fundamentals remain solid," Mathivanan said. The company's guidance GOV growth guidance indicates "relatively stable growth rates," while its EBITDA outlook "points to healthy incremental margins and steady margin expansion," he added.
The analyst wrote that DoorDash will likely exhibit "better resiliency during macro volatility.&#8221; The recently announced acquisitions of Deliveroo and SevenRooms should enable the company to expand into new geographies and "enhance the platforms&#8217; restaurant services," he stated.
DASH Price Action: At the time of publication on Wednesday, shares of DoorDash had declined by 6.14% to $178.44.
Read More: <a href="https://www.benzinga.com/news/25/04/45045012/sabre-divests-hospitality-arm-tpg-plans-debt-reductioncore-platform-focus"> DoorDash To Boost Global Presence With $3.9 Billion Acquisition Of UK&#8217;s Deliveroo</a>
Photo: Shutterstock

Earnings Beats

Price Target

DASH

DoorDash Misses On Q1 Sales But 2025 Order Outlook Sparks Price Target Hikes

<a href="https://www.youtube.com/watch?v=M1STr27Vbts">https://www.youtube.com/watch?v=M1STr27Vbts</a>
&nbsp;

Macro Economic Events

Economics

Federal Reserve

Fed Chair Powell Says We Can Afford To Be Patient, No Real Cost To Our Waiting; Not Dismissing Soft Data, But The Link Between Consumer Sentiment And Demand In Recent Years Was Weak, This Is An Outsized Changed In Sentiment Though; We Can Be More, Or Less, Supportive Of Demand; That's An Inefficient Way To Address Supply Chain Issues

Flotek Industries shares are trading higher after the company reported better-than-expected Q1 financial results.

CURI

CuriosityStream shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 sales guidance above estimates.

Fed Chair Powell Says Now In A New Phase Where Administration Is Beginning Trade Talks, Has Potential To Change Picture Materially Or Not; Trade Issues Are 'For The Administration To Do'; Big Spike In Imports To Beat Tariffs Should Reverse In Q2, Likely Net Exports To Have Large Positive Contribution To GDP; Will Be Harder To Make A Clean Assessment Of U.S. Demand, Final Sales To Private Domestic Buyers Was Likely Flattered A Bit By Front Running

Offerings

Spire Files For Mixed Shelf Offering; Size Not Disclosed

Eos Energy Enterpises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) shares are trading higher Wednesday after the company reported better-than-expected <a href="https://www.benzinga.com//node/45235078">first-quarter financial results.</a>
What To Know: Eos reported a loss of 17 cents, beating the consensus estimate of a 21 cent-loss. In addition, the company reported sales of $10.46 million, beating the consensus estimate of $10.40 million and representing a 58% year-over-year increase.
The company ended the quarter with $111.7 million in cash. It also reported a commercial opportunity pipeline of $15.6 billion.
&#8220;The Eos team delivered solid operating results. We are starting to see the product cost-out benefits combined with higher manufacturing output,&#8221; said Joe Mastrangelo, Eos CEO.
&#8220;Year-to-date, the team has already surpassed total 2024 shipments, and during&nbsp;Q1&nbsp;the operations team set production records across all key processes showing the ability to scale operations. We continue to position the Company for long-term profitable growth and believe that American-made long duration energy storage will play a critical role in helping the country achieve energy independence.&#8221;
Outlook: The company sees fiscal-year sales from $150 million to $190 million, versus the consensus estimate of $167.08 million.
See Also: <a href="https://www.benzinga.com/news/global/25/05/45261215/whats-going-on-with-zeekr-stock-today">What&#8217;s Going On With Zeekr Stock Today?</a>
EOSE Price Action: At the time of writing, Eos stock is trading 32% higher at $6.64, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: via Shutterstock

EOSE

Eos Energy Stock Is Moving Higher: What's Going On?

Fed Chair Powell Says Fortunately Since Then Unemployment Rate Has Been Moving Sideways; So Concern About Further Cooling Has Gotten A Lot Less; Can't Say How Much Of A Rise In Unemployment Rate Is Tolerable; Need To Look At Both Unemployment And Inflation; If Did See Significant Labor Market Deterioration, Of Course We Would Look To Be Able To Support That; Would Hope That At Same Time Inflation Was Not Getting Very Bad; Will Have To Wait And See

Comstock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LODE#AMEX">LODE</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-08. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Comstock to report an earnings per share (EPS) of $-0.20.
The announcement from Comstock is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Performance in Previous Earnings</h3>
The company's EPS beat by $0.14 in the last quarter, leading to a 1.89% drop in the share price on the following day.

<img src="https://www.benzinga.com/files/images/story/2025/1746644757_0.png" alt="eps graph" />
<h3>Tracking Comstock's Stock Performance</h3>
Shares of Comstock were trading at $2.54 as of May 06. Over the last 52-week period, shares are down 10.82%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/LODE/earnings">To track all earnings releases for Comstock visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

LODE

Insights Ahead: Comstock's Quarterly Earnings

Press Releases

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Power Nickel's (TSX.V: PNPN) Hole Delivers "BIG"- Gold Terra (TSX.V: YGT) Developments and Exploration Progress Reported – More Stocks Inside!

Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

KTTA

KTTAW

OGEN

PNPNF

TSXV:PNPN

TSXV:YGT

YGTFF

Alzamend Neuro

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

180 Life Sciences

Azitra

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Galecto

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Oragenics

Palisade Bio

Palatin Techs

Sunshine Biopharma

SILO Pharma

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Theriva Biologics

VivoSim Labs

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

Xenetic Biosciences

EF Hutton

Comments

Pasithea Therapeutics

Pasithea Therapeutics (KTTA) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル